MRSA is a type of bacteria that can cause infections in humans. MRSA is resistant to many antibiotics, and it can be difficult to treat. The global MRSA drugs market is expected to grow at a CAGR of 5.5% from 2021-2030. North America accounted for the largest share of the global MRSA drugs market in 2018 owing to the high prevalence rate of MRSA among patients with chronic diseases such as diabetes mellitus and HIV/AIDS in this region as well as increased awareness about the disease among healthcare professionals and patients alike which has led them towards adopting preventive measures against infection with this bacterium such as vaccination or antibiotic prophylaxis before surgery or invasive procedures like dialysis treatment or chemotherapy treatment for cancer patients which are major drivers for growth in this region over the forecast period from 2021-2030. Global MRSA Drugs Market By Type (Tetracycline, Folate antagonist, Cephalosporin, Lipopeptides, Oxazolidinone), By Application (Hospital) And By Region (North America) Forecast From 2021 To 2030. MRSA is a type of bacteria that can cause infections in the skin, lungs, and bloodstream. MRSA is resistant to many antibiotics. The most common treatment for MRSA is vancomycin.
Industry Growth Insights published a new data on “MRSA Drugs Market”. The research report is titled “MRSA Drugs Market research by Types (Tetracycline, Folate antagonist, Cephalosporin, Lipopeptides, Oxazolidinone, Lipoglycopeptide), By Applications (Hospital, Research, Clinic, Other), By Players/Companies Allergan, Merck, Pfizer, Theravance Biopharma, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica, Baxter, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
MRSA Drugs Market Research Report
By Type
Tetracycline, Folate antagonist, Cephalosporin, Lipopeptides, Oxazolidinone, Lipoglycopeptide
By Application
Hospital, Research, Clinic, Other
By Companies
Allergan, Merck, Pfizer, Theravance Biopharma, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica, Baxter, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global MRSA Drugs Market Report Segments:
The global MRSA Drugs market is segmented on the basis of:
Types
Tetracycline, Folate antagonist, Cephalosporin, Lipopeptides, Oxazolidinone, Lipoglycopeptide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Merck
- Pfizer
- Theravance Biopharma
- Absynth Biologics
- AmpliPhi Biosciences
- AstraZeneca
- Basilea Pharmaceutica
- Baxter
- Cellceutix
- Cempra
- CrystalGenomics
- Debiopharm
- Galapagos
- GSK
- KYORIN Pharmaceutical
- Lytix Biopharma
- Melinta Therapeutics
- Nabriva Therapeutics
- NovaDigm Therapeutics
Highlights of The MRSA Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tetracycline
- Folate antagonist
- Cephalosporin
- Lipopeptides
- Oxazolidinone
- Lipoglycopeptide
- By Application:
- Hospital
- Research
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the MRSA Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
MRSA drugs are medications that can help treat infections caused by the MRSA bacteria. These drugs can be taken orally, injected into a vein, or applied topically to the skin. Some of these medications work by killing the MRSA bacteria while others work by preventing its growth.
Some of the major companies in the mrsa drugs market are Allergan, Merck, Pfizer, Theravance Biopharma, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica, Baxter, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics.
The mrsa drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. MRSA Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. MRSA Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. MRSA Drugs Market - Supply Chain
4.5. Global MRSA Drugs Market Forecast
4.5.1. MRSA Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. MRSA Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. MRSA Drugs Market Absolute $ Opportunity
5. Global MRSA Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. MRSA Drugs Market Size and Volume Forecast by Type
5.3.1. Tetracycline
5.3.2. Folate antagonist
5.3.3. Cephalosporin
5.3.4. Lipopeptides
5.3.5. Oxazolidinone
5.3.6. Lipoglycopeptide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global MRSA Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. MRSA Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Research
6.3.3. Clinic
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global MRSA Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. MRSA Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global MRSA Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. MRSA Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global MRSA Drugs Demand Share Forecast, 2019-2026
9. North America MRSA Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America MRSA Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America MRSA Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Research
9.4.3. Clinic
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America MRSA Drugs Market Size and Volume Forecast by Type
9.7.1. Tetracycline
9.7.2. Folate antagonist
9.7.3. Cephalosporin
9.7.4. Lipopeptides
9.7.5. Oxazolidinone
9.7.6. Lipoglycopeptide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America MRSA Drugs Demand Share Forecast, 2019-2026
10. Latin America MRSA Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America MRSA Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America MRSA Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Research
10.4.3. Clinic
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America MRSA Drugs Market Size and Volume Forecast by Type
10.7.1. Tetracycline
10.7.2. Folate antagonist
10.7.3. Cephalosporin
10.7.4. Lipopeptides
10.7.5. Oxazolidinone
10.7.6. Lipoglycopeptide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America MRSA Drugs Demand Share Forecast, 2019-2026
11. Europe MRSA Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe MRSA Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe MRSA Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Research
11.4.3. Clinic
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe MRSA Drugs Market Size and Volume Forecast by Type
11.7.1. Tetracycline
11.7.2. Folate antagonist
11.7.3. Cephalosporin
11.7.4. Lipopeptides
11.7.5. Oxazolidinone
11.7.6. Lipoglycopeptide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe MRSA Drugs Demand Share, 2019-2026
12. Asia Pacific MRSA Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific MRSA Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific MRSA Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Research
12.4.3. Clinic
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific MRSA Drugs Market Size and Volume Forecast by Type
12.7.1. Tetracycline
12.7.2. Folate antagonist
12.7.3. Cephalosporin
12.7.4. Lipopeptides
12.7.5. Oxazolidinone
12.7.6. Lipoglycopeptide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific MRSA Drugs Demand Share, 2019-2026
13. Middle East & Africa MRSA Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa MRSA Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa MRSA Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Research
13.4.3. Clinic
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa MRSA Drugs Market Size and Volume Forecast by Type
13.7.1. Tetracycline
13.7.2. Folate antagonist
13.7.3. Cephalosporin
13.7.4. Lipopeptides
13.7.5. Oxazolidinone
13.7.6. Lipoglycopeptide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa MRSA Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global MRSA Drugs Market: Market Share Analysis
14.2. MRSA Drugs Distributors and Customers
14.3. MRSA Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Theravance Biopharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Absynth Biologics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AmpliPhi Biosciences
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AstraZeneca
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Basilea Pharmaceutica
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Baxter
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Cellceutix
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cempra
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. CrystalGenomics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Debiopharm
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Galapagos
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. GSK
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. KYORIN Pharmaceutical
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Lytix Biopharma
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Melinta Therapeutics
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Nabriva Therapeutics
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. NovaDigm Therapeutics
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook